These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11334309)

  • 1. Candida albicans molecular biology reaches its maturity.
    Larriba G; Rubio Coque JJ; Ciudad A; Andaluz E
    Int Microbiol; 2000 Dec; 3(4):247-52. PubMed ID: 11334309
    [No Abstract]   [Full Text] [Related]  

  • 2. Candida albicans - Biology, molecular characterization, pathogenicity, and advances in diagnosis and control - An update.
    Dadar M; Tiwari R; Karthik K; Chakraborty S; Shahali Y; Dhama K
    Microb Pathog; 2018 Apr; 117():128-138. PubMed ID: 29454824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human fungal pathogen Candida albicans in the postgenomic era: an overview.
    Kabir MA; Hussain MA
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):121-34. PubMed ID: 19622061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential Targets for Antifungal Drug Discovery Based on Growth and Virulence in Candida albicans.
    Li X; Hou Y; Yue L; Liu S; Du J; Sun S
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5885-91. PubMed ID: 26195510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Candida albicans filamentation for antifungal drug development.
    Vila T; Romo JA; Pierce CG; McHardy SF; Saville SP; Lopez-Ribot JL
    Virulence; 2017 Feb; 8(2):150-158. PubMed ID: 27268130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans.
    Cui J; Ren B; Tong Y; Dai H; Zhang L
    Virulence; 2015; 6(4):362-71. PubMed ID: 26048362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenicity determinants of Candida albicans: potential targets for immunotherapy?
    Matthews RC
    Microbiology (Reading); 1994 Jul; 140 ( Pt 7)():1505-11. PubMed ID: 8075793
    [No Abstract]   [Full Text] [Related]  

  • 8. First Case of Echinocandin-Resistant Candida albicans in Korea.
    Park MS; Park JE; Song DJ; Huh HJ; Park S; Kang CI; Shin JH; Lee NY
    Ann Lab Med; 2017 Nov; 37(6):556-558. PubMed ID: 28841000
    [No Abstract]   [Full Text] [Related]  

  • 9.
    Gong Y; Li T; Yu C; Sun S
    Front Cell Infect Microbiol; 2017; 7():520. PubMed ID: 29312897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomics to study Candida albicans biology and pathogenicity.
    Thomas DP; Pitarch A; Monteoliva L; Gil C; Lopez-Ribot JL
    Infect Disord Drug Targets; 2006 Dec; 6(4):335-41. PubMed ID: 17168799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candida morphogenesis and host-pathogen interactions.
    Whiteway M; Oberholzer U
    Curr Opin Microbiol; 2004 Aug; 7(4):350-7. PubMed ID: 15358253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal Compounds against
    Liu X; Ma Z; Zhang J; Yang L
    Biomed Res Int; 2017; 2017():4614183. PubMed ID: 29445739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular biology of dimorphism in Candida albicans].
    Cho T
    Nihon Saikingaku Zasshi; 1999 Apr; 54(2):415-21. PubMed ID: 10356953
    [No Abstract]   [Full Text] [Related]  

  • 14. Candida albicans: biology, genetics, and pathogenicity.
    Shepherd MG; Poulter RT; Sullivan PA
    Annu Rev Microbiol; 1985; 39():579-614. PubMed ID: 3904613
    [No Abstract]   [Full Text] [Related]  

  • 15. Vocation, location, vocation: researching Candida pathogenesis.
    Sturtevant J
    Virulence; 2014; 5(8):773-4. PubMed ID: 25483865
    [No Abstract]   [Full Text] [Related]  

  • 16. Contribution of Aspartic Proteases in Candida Virulence. Protease Inhibitors against Candida Infections.
    Monika S; Małgorzata B; Zbigniew O
    Curr Protein Pept Sci; 2017; 18(10):1050-1062. PubMed ID: 27514853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of RPS41 in Biofilm Formation, Virulence, and Hydrogen Peroxide Sensitivity in Candida albicans.
    Lu H; Xiong J; Shang Q; Jiang Y; Cao Y
    Curr Microbiol; 2016 Jun; 72(6):783-7. PubMed ID: 26952720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruption of the intestinal mucosal barrier in Candida albicans infections.
    Yan L; Yang C; Tang J
    Microbiol Res; 2013 Aug; 168(7):389-95. PubMed ID: 23545353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide functional analysis in Candida albicans.
    Motaung TE; Ells R; Pohl CH; Albertyn J; Tsilo TJ
    Virulence; 2017 Nov; 8(8):1563-1579. PubMed ID: 28277904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candida albicans, the opportunist. A cellular and molecular perspective.
    Dupont PF
    J Am Podiatr Med Assoc; 1995 Feb; 85(2):104-15. PubMed ID: 7877106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.